Letter to the Editor: Statins and COVID-19: Efficacy Still to Be Proven.

We read with interest the article by Bloom et al reporting liver biochemistry-associated trends, etiologies, and outcomes in 60 patients with coronavirus disease 2019 (COVID-19). The authors reported that 69% of the patients had abnormal liver function tests (LFTs) on admission and 93% during their hospital stay, with an aspartate aminotransferase (AST) predominance. These results are similar to our own experience of 234 patients admitted with COVID-19 according to World Health Organization (WHO) diagnostic guidelines.